Read on Twitter
Very promising news that the Pfizer/BioNtech #COVID19 #vaccine candidate BNT162b2 demonstrated more than 90% efficacy in the first phase 3 interim analysis (after 94 events). https://biontechse.gcs-web.com/news-releases/news-release-details/pfizer-and-biontech-announce-vaccine-candidate-against-covid-19/
In the phase 3 trial, 43,000+participants enrolled to test Pfizer/BioNTech’s 2-dose #mRNA #vaccine. The efficacy estimate could change w/longer follow up. Questions remain-full report w/details of all endpoints/safety key. Much better news than expected! https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/
Track all #COVI19 #vaccines in phase 1, 2, 3 clinical trials on our vaccine tracker and check out the BioNTech/Pfizer BNT162b2 vaccine page for details of the ongoing trials https://covid19.trackvaccines.org/vaccines/6/
Did you know BioNTech/Pfizer have 5 formulations of their BNT162 #vaccine in clinical trials? Take a look at where-BNT162a1, BNT162b1, BNT162b3, BNT162c2-are being tested & in which phase. Most trackers don’t distinguish between these, but we make it easy: https://covid19.trackvaccines.org/vaccines/
And be sure to check out this great thread by @kakape highlighting all of the important caveats 
https://twitter.com/kakape/status/1325771586067197954
https://twitter.com/kakape/status/1325771586067197954
